Skip to main content
. 2014 Dec 10;77(2):363–369. doi: 10.1038/pr.2014.183

Figure 4.

Figure 4

Adrenergic genotype and change in ventricular systolic and diastolic dysfunction (stable HF cohort). Regression analyses were performed to assess association of ADR genotypes with change in ventricular systolic and diastolic function on serial echocardiograms in 35 stable HF patients. Graphs show parameter estimate of change in echocardiographic measurements for each additional ADR risk genotype stratified by β-blocker use. Red, on no β-blockers; black, on β-blockers. There was a greater decline in LV ejection fraction for every additional ADR risk genotype, but this association was not seen in patients receiving β-blockers (interaction P = 0.003 vs. those not receiving β-blockers). There was a greater increase in LV end-systolic volume z-score for every additional ADR risk genotype, but this did not reach statistical significance between those receiving vs. those not receiving β-blockers (interaction P = 0.12). There was a greater decline in peak mitral E wave velocity for every additional ADR risk genotype, but this association was not seen in patients receiving β-blockers (interaction P < 0.001 vs. those not receiving β-blockers). There was a greater decline in early diastolic tricuspid annular velocity with each additional ADR risk genotype, but this association was not seen in patients receiving β-blockers (interaction P = 0.001 vs. those not receiving β-blockers) (n = 7 for 0, n = 22 for 1, n = 22 for 2, and n = 4 for 3 risk genotypes).